Nonsmall-cell lung cancer is the leading cause of deathfrom cancer in men and women in the United States, and worldwideit kills more than 1 million people annually. Approximatelytwo thirds of patients with nonsmall-cell lung cancerpresent with locally advanced or metastatic disease that requiressystemic therapy in addition to surgery or radiation therapy.The good news is that the results of systemic therapy are improving:chemotherapy prolongs survival and improves the quality of lifefor patients with nonsmall-cell lung cancer. The badnews is that systemic therapy is still woefully inadequate:only 30 to 40 percent of . . . [Full Text of this Article]
Source Information
From the Hamon Center for Therapeutic Oncology Research (J.E.D., J.D.M.) and the Departments of Internal Medicine (J.E.D., J.D.M.) and Pharmacology (J.D.M.), University of Texas Southwestern Medical Center, Dallas.
This article has been cited by other articles:
Liu, Z., Li, H., Derouet, M., Filmus, J., LaCasse, E. C., Korneluk, R. G., Kerbel, R. S., Rosen, K. V.
(2005). ras Oncogene Triggers Up-regulation of cIAP2 and XIAP in Intestinal Epithelial Cells: EPIDERMAL GROWTH FACTOR RECEPTOR-DEPENDENT AND -INDEPENDENT MECHANISMS OF ras-INDUCED TRANSFORMATION. J. Biol. Chem.
280: 37383-37392
[Abstract][Full Text]
Dicker, A. P., Rodeck, U.
(2005). Predicting the Future From Trials of the Past: Epidermal Growth Factor Receptor Expression and Outcome of Fractionated Radiation Therapy Trials. JCO
23: 5437-5439
[Full Text]
Kobayashi, S., Ji, H., Yuza, Y., Meyerson, M., Wong, K.-K., Tenen, D. G., Halmos, B.
(2005). An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor. Cancer Res.
65: 7096-7101
[Abstract][Full Text]